We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Coherus BioSciences

News List

Coherus BioSciences Announces Filing of Patent Infringement Suit Against Amgen Directed to Amgen’s Humira Biosimilar Formulation firstwordpharma
January 28, 2019
Coherus BioSciences, Inc. (Nasdaq: CHRS), a commercial biosimilar company, today announced it has filed suit against Amgen in the United States District Court (Delaware) alleging that Amgen's Humira® biosimilar, Amgevita™, infringes Coherus' U.S. patents
FDA Approves Udenyca，Udenyca is Coherus’ first drug to receive FDA or EC approval americanpharmaceuticalreviewpharmaceutical-technol
November 10, 2018
Coherus BioSciences announced the U.S. Food and Drug Administration (FDA) has approved Udenyca (pegfilgrastim-cbqv), the first pegfilgrastim biosimilar approved by both the FDA and the European Commission (EC) for patients with cancer receiving myelosuppr